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Summary.-Affinity-purifiedantibodiestocarcinoembryonicantigen(CEA)havebeen
injected into immune-suppressed micebearing xenografts ofhuman breasttumours.
It has been shown that the antibodies localized in the tumours but not in normal
tissues. The degree of tumour localization correlates with the amount of tumour
CEA, and is unaffected by levels of circulating CEA or CEA/anti-CEA immune
complexes.
THE CONCEPT of injecting anti-tumour-
cell antibodies to localize neoplasms was
first introduced in experimental systems
by Pressman (1957). Since then, success
has been achieved with human tumours
using antibodies to the carcinoembryonic
antigen (CEA) (Gold & Freedman, 1965). It
has been demonstrated that such radio-
labelled antibodies localized preferentially
in human colonic neoplasms xenografted
into animals (Primus et al., 1973; Mach
et al., 1974). More recently, localization
of anti-CEA antibodies has been attained
in patients, but only when the blood-pool
backgroundwassubtractedbyacomputer-
ized technique (Goldenberg et al., 1978;
Dykes et al., 1980; Mach et al., 1980).
Although some workers have achieved
almost complete success with this method,
others have expressed doubts as to its
present suitability for routine clinical use
(Mach et al., 1980).
Many breast carcinomas produce CEA,
the level of circulating CEA being stage-
dependent (Laurence et al., 1972; Coombes
et al., 1980; Tormey & Waalkes, 1978).
The need for early detection of systemic
metastases and metastatic involvement of
inaccessible internal mammary lymph
nodes has prompted us to examine the
40
localizing potential of anti-CEA in human
breast carcinomas. The establishment of
xenografts ofhuman breast carcinomas in
immune-suppressed mice (Bailey et al.,
1980) has enabled us to examine different
tumours and thus investigate the kinetics
oftumour lbcalization and its relationship
to the CEA content of the tumour before
starting clinical studies.
MATERIALS AND METHODS
Animals and tumours.-Four-week-old,
female CBA/lac mice, weighing on average
20g, wereimmunesuppressed bythymectomy
and total-body irradiation (6 gray) preceded
by i.p. injection of cytosine arabinoside (200
mg/kg) (Steel et al., 1978). Three different
xenograft lines of human breast carcinomas
were used (HX99, HX106 and HX104)
(Bailey et al., 1981). These have been shown
to maintain their characteristic human
morphology, chromosome number and
tumour-marker expression throughout pass-
aging. HX104 was used at Passage 6, HX99
at Passage 7 and 8 and HX106 at Passage 8.
The tumours were implanted s.c. bilaterally
in the flanks 3-5 weeks before use.
The antibody and iodine labelling.-The
CEA used as immunogen and for coupling of
Sepharose 4B (see below) was isolated from
hepatic metastases ofa human colonic carcin-V. MOSHAKIS ET AL.
oma and purified to satisfy the criteria pre-
viously described (Westwood & Thomas,
1975; Westwood, 1978). Anti-CEA sera were
raised by monthly s.c. injections of a goat
with 100 jug ofCEA, emulsified with Freund's
adjuvant. The first 2 CEA injections were in
complete adjuvant. Regular bleeds were
taken after the 4th injection, and the goat
was exsanguinated 2 weeks after the 7th
injection. The y-globulin fraction of the
immune serum was obtained and the solution,
in phosphate-buffered saline (PBS) (015M,
pH 7) was passed over a column comprising
CEA (15 mg) covalently bound to Sepharose
4B (10 ml). The column was washed with
01M PBS to remove all unbound protein, and
anti-CEA antibodies were recovered from the
column using 6M guanidine HCI in 01M PBS.
The guanidine HCI was removed by dialysis.
The affinity-purified goat anti-CEA anti-
bodies were labelled with 125I, using chlor-
amine-T (Greenwood et al., 1963). Typically,
an activity of 1 ,uCi/,ug was achieved. IgG
from a non-immunized goat was labelled with
1311 by the-same method and admixed with
the specific antibody before injection. Column
chromatography (Sephacryl S-300) of the
radiolabelled proteins demonstrated the
absence of aggregated material in the void
volume.
Radiolocalization.-Simultaneous i.v. in-
jection of 15 ,ug each of 1251-anti-CEA and
goat 1311 IgG was given to tumour-bearing
and tumour-free animals. At intervals of
between 1 and 96 h after injection, the
animals were exsanguinated and tumours and
organs (salivary gland, thyroid, heart, lungs,
liver, spleen, stomach, kidney and intestine)
were removed. After weighing each tissue,
radioactivity was measured in an L.K.B. 1280
ultra-gamma counter. Gel-filtration chroma-
tography of the plasma of the injected ani-
mals at death was performed to demonstrate
circulating CEA/anti-CEA immune com-
plexes.
The results were expressed in the form of a
Localization Index, which is the ratio of
specific (1251) to nonspecific (1311) antibody
in normal tissues or tumour, divided by the
same ratio in blood. This is similar to the
localization ratio of Primus et al. (1973) and
the specificity index of Mach et al. (1974)
except that the former authors made a com-
parison with the ratio in the injected solution
and the latter with liver. We chose blood,
because this gives the closest comparison to
an external photoscan of a patient when the
activity in the blood pool is subtracted
(Goldenberg et al., 1978; Dykes et al., 1980).
Demonstration of CEA in tumours and
plasma.-CEA was demonstrated at the histo-
logical level in conventionally prepared tissue
sections, using methods and reagents de-
scribed previously (Heyderman & Neville,
1976; Ormerod, 1978). In addition, the CEA
content of xenografted tumours and in the
plasmas of animals was measured by the
radioimmunoassay methods ofLaurence et al.
(1972). Each tumour was homogenized at
0°C in 0.9% saline. 2M perchloric acid was
then added to each homogenate and the mix-
ture was left at 00C for 30 min. Precipitated
protein was removed by centrifugation and
the supernatant was well dialysed with dis-
tilled water at 4°C. The radioimmunoassay
was then performed.
Chromatography of plasma samples.-For
the purpose ofdetecting CEA/anti-CEA com-
plexes, each sample of plasma was applied to
a column ofSephacryl S-300 (0.9 x 60 cm) and
eluted with 01M phosphate buffer (pH 7.5)
at a rate of 5 ml/h. 0(5ml fractions were
collected and the radioactivity of each
fraction (1251 and 1311) was measured using
an LKB 1280 ultra-gamma counter.
RESULTS
Two to three weeks after tumour im-
plantation (range of tumour wet wt
36-98 mg; mean 67 + 6 mg), the mice were
injected i.v. with equal amounts by weight
of 1251-labelled anti-CEA and 13l-labelled
normal y-globulin. At each sampling
time after injection at least 3 mice,
carrying a total of 3-6 tumours, were
exsanguinated and tumours and organs
removed for estimation of the radioacti-
vity. Altogether there were 10 experi-
ments, using 211 animals carrying collec-
tively 328 tumours. In addition, 2 non-
tumour-bearing animals, injected with the
same amounts of antibodies, were ex-
sanguinated at each sampling time. Table
I shows typical results for one of the
tumours (HX99) 24 h after injection. It
can be seen that the tumour was the only
tissue which showed specific localization
of the anti-CEA antibodies. This tumour
was the only 1 of the 3 to show a high
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TABLE I.-Specific (125I-anti-CEA) and
non-specific (13lI-normal) Ig activity in
tissues 24 h after injection of antibodies.
Values of radioactivity are mean + s.e.
in 4 animals (HX 99). The localization
index is calculated from the values in the
first twocolumns
TABLE II.-Relation between tumour local-
ization, immunoperoxidase staining and
direct CEA estimation in 3 breast
adenocarcinoma xenografts. Values are
mean+ s.e. (6 tumours from ecach line),
(the difference in LI between HX106 and
HX104 was not significant)
Tissue
Tumour
Blood
Liver
Thyroid gland
Salivary gland
Stomach
Intestine
Heart
Lung
Spleen
Kidney
1251-anti-
CEA
ct/min/mg*
293 + 39
222 + 22
65+12
58+ 8
63+19
49+17
51+12
48+ 7
47 + 16
36+ 8
28+ 11
1311-normal
Ig
ct/min/mg*
196+ 28
553 + 66
120+ 29
131+ 27
123+19
118+ 20
126+18
117+ 23
'I Ila 'Io 1U03
98
92-
* Wet weight.
t Localization index:
1251
tissue or tumour 1311 divided b;
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FIG. 1.-Localization index in
human breast adenocarcinoma
For definition oflocalization inc
0, HX99 (CEA+ +, see Table
104 (CEA+); A, HX106 (CE]
LIt
3-7
1-0
1*3
1-1
1-3
1-0
1-0
1-0
'I I
Tumour
HX 99
HX 106
HX 104
Tumour
CEA
(/Lg/g)
14-0+4-0
1-1+0-3
0-6+0-01
Plasma
CEA
(ng/ml)
377 + 59
463 + 26
257 + 34
Maximum CEA
LI* staint
90+1-3
1-5+0-6
2-0+0-8
++
+
+
* I.e. at 96 h after injection.
t The strength of the immunoperoxidase stain for
CEA on an arbitrary scale.
+16 1l0 degree of specific localization (Fig. 1);
+12 0-8 HX106 and HX104 showed little or no
localization of the anti-CEA. Table II
compares the maximum localization index
y blood 1251 (at 96 h after injection) for each tumour,
the levels ofCEA circulating in the plasma
of the mice, the CEA content of each
tumour and the result of immunohisto-
chemical stain for CEA. It is ofinterest to
note that the amount of CEA circulating
* in the plasma did not correlate with the
* amountofCEA storedinthe tumour. With
this series of 3 tumour lines, the degree of
localization of radiolabelled anti-CEA
correlated with the amount ofCEA in the
* tumour.
* When the tumours were allowed to grow
to a larger size (mean weight 172 + 23 mg)
by delaying injection of the radiolabelled
*/ antibodies until 5 weeks after implanta-
* | tion, a lower localizadtion index was
obtained at all times after injection (Fig.
* 2). A similar result was obtained- with
S human colonic tumours xenografted in
8 8 the hamsters by Primus et al. (1973); also
____ i Mach et al. (1974) showed lower specificity
~- indices in more necrotic tumours. Lower-
A A i ing the amount of antibody injected into
I , the mice also lowered the localization
24 48 96 index (Fig. 2).
To investigate method& of ,increasing
3 different the activity localized in the tjnmour, we
xenografts. gave a second injection of radiolabelled
lex, see text. anti-CEA and normal Ig 24 h after the
II); 0~ HX- first injection; some of the mice received
1)
I
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FIG. 2.-Localization index in one human
breast-adenocarcinoma xenograft (HX99)
at different tumour weights and after
different amounts of anti-CEA injected.
The localization index decreases when
larger tumours are used, and when lower
amounts of antibody are injected. Each
line represents a separate experiment. 4-6
tumours at each time point ofeach experi-
ment. *, Weight=63+ 13 mg; antibody
injected= 15 ,ug. *, Weight=69± 11 mg;
antibody injected=3.5 ,ug. *, Weight=
172+23 mg; antibody injected= 15 pg.
(For clarity s.e. values have been omitted;
the scatter ofthe points was as in Fig. 1.)
a 3rd injection on the 3rd day. These
manoeuvres increased the activity in each
tumour but at the expense ofthe localiza-
tion index (Fig. 3).
When samples of plasma were passed
over Sephacryl columns, the bulk of the
radioactivity was eluted in a position
corresponding to the mol. wt of IgG (Fig.
4). Tumour-bearing mice showed an in-
creased amount of labelled specific anti-
body eluting in the void volume of the
column. This peak was absent from the
profile of the 131I-labelled normal Ig and
15pg
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FIt. 3. (a) Localization index after 15 jug,
30 tg and 45 jg of antibody injected.
Arrows indicate the timing ofthe injections.
(b) Specific activity (125I-anti-CEA) in
tumour (-) and blood (---) after 15 jug,
30 ,ug and 45 iLg of antibody injection.
Arrowsindicate thetiming oftheinjections.
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FIG. 4.-Column chromatography of plasma
after injection of antibody. A marks the
position of the voided material which we
assume represents CEA/antibody com-
plexes. B marks the position of the labelled
IgG. 0, Tumour-bearing animal; 0,
Tumour-free animal.
was greatly reduced in the profile of
specific antibody obtainedfrom theplasma
of mice without tumours. We assume,
although we did not prove it, that this
voided material represents CEA-anti-CEA
immune complexes. The peak of 1311-
labelled normal Ig was normalized to
coincide with the 125I peak and subtracted
from it. The remaining 1251 activity was
the voided material. We used this
subtraction method to estimate the
amount of radioactive material eluted as
immune complex, andtherebyfollowedthe
clearance of these complexes from the
blood; there was no significant difference
in the rate of clearance of immune com-
plexes between mice bearing HX99
tumours (which gave a high localization
index) and those bearing HX106 tumours
(.D
0)
0
0 0,-O
Hours
FIG. 5.-Upper graph: 1251-anti-CEA clear-
ance from blood after injection, as measured
by gamma counter. Lower graph: Immune
complex clearance from blood after injec-
tion, as measured by column chromato-
graphy. (HX99 (0) showed high localiza-
tion. HX106 (0) showed no localization.)
(which gave no specific localization) (Fig.
5).
We observed that, in both tumour-
bearing and tumour-free mice, the specific
(anti-CEA) IgG was cleared more rapidly
in the first hour after injection than the
nonspecific Ig. The specific 1251-labelled
IgG also contained a small amount of
aggregated material (Fig. 4) which was
absent from the 131I-labelled nonspecific
Ig. It is possible that the anti-CEA
antibodies were more susceptible to
damage during iodination, and that this
resulted in an initial difference in be-
haviour between the two types of IgG.
To ascertain whetherimmune complexes
of CEA and anti-CEA might localize in
tumours through their content of histio-
cytes, we took C57 BL mice carrying a
murine fibrosarcoma (FS6) (Mantovani
et al., 1977), which has a macrophage
population of 25%, and administered both
14-
12-
10-
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1251-labelled anti-CEA with CEA at
equivalence and 1311-labelled goat Ig.
No specific localization in the tumour was
detected.
DISCUSSION
Other workers have successfully demon-
strated the localization of specific anti-
CEA antibodies in human colonic car-
cinoma xenografted either into hamsters
(Primus et al., 1973) or into nude mice
(Mach et al., 1974). We have expanded this
work by showing that anti-CEA anti-
bodies will localize in human breast
carcinomas.
The quantity of CEA circulating in the
plasma of these mice will depend on the
rate ofsynthesis and release ofCEA by the
tumour, and also on its rate of clearance.
Our results suggest that the degree of
localization of specific antibodies is de-
pendent on the amount of CEA stored in
the tumour, and that the amount of
circulating CEA is irrelevant. The latter
observation accords with the clinical
experience recorded by Goldenberg and
his co-workers (Goldenberg et at., 1978;
Nagell et al., 1980; Primus et al., 1980).
This is important since it indicates that
plasma CEA levels cannot be used to
select patients for the application of this
technique. The amount of CEA in the
tumour as estimated either by an immuno-
histochemical stain or by extraction and
subsequent radioimmunoassay may be a
more reliable guide.
The results accord with the hypothesis
that the anti-CEA antibodies are localized
inthetumourbyreactionwith CEAatthat
site. In relation to this, we have shown by
autoradiography that monoclonal anti-
bodies raised to cell-surface antigens of
human teratoma xenografts localize in
close association to viable tumour cells
after in vivo administration of the anti-
bodies (Moshakis et al., 1981).
Many tumours contain large numbers of
histiocytes, and it could be visualized that
specific antibodies would be localized in
tumours, owing to uptake of immune
complexes by the histiocytes. Although
we looked for evidence to support this
alternate hypothesis we found none. The
levels of circulating immune complexes
were similar in mice bearing HX99
tumours and those bearing HX106, yet
one tumour showed a high degree of
localization ofspecific antibody, whilst the
other had none. Furthermore, anti-CEA
alone and anti-CEA/CEA complexes failed
to localize in a murine fibrosarcoma which
is known to have a high percentage of
macrophages in its cell population.
Although in this system, using these
particular tumours, the localization index
increased with time, the total amount of
radioactivity in the tumours decreased.
The optimal time at which to use an
external radioscan in patients is balanced
between the two factors. The other point
to note is that at all times, apart from the
tumour, the most radioactive tissue was
the blood. This emphasizes the need for
a technique to subtract the activity in the
bloodpool.
Having established the usefulness of
this model system in relation to the well-
known antigen CEA, we are now in a
position to extend this work to other less
well studied antigens and to patients.
Experiments have started using affinity-
purified antibodies to the epithelial mem-
brane antigen (EMA) expressed by human
breast carcinomas (Heyderman et al.,
1979; Sloane & Ormerod, 1981) and to
teratomas, through the use of monoclonal
antibodies (Moshakis et al., 1981). We
hope that this latter approach can, in
time, be extended to the study of human
breast carcinomas.
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